Navigation Links
Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
Date:7/27/2009

weeks, or the 22 week endpoint.

"We are excited that our trial demonstrated safety and efficacy of our HSC product, which contains Wnt proteins and other growth factors important to hair follicle maintenance and growth," said Dr. Gail K. Naughton, CEO of Histogen. "Wnt signaling has been shown by a number of experts in the field to be responsible for initiating epidermal stem cells to form new hair follicles in mice, and to be important in maintaining the hair inducing activity from existing follicles. Histogen's trial is the first demonstration that compounds containing bioactive Wnt increase hair growth in humans."

While additional clinical evaluation is needed to further examine product safety, efficacy and treatment specifications, the preliminary clinical trial of HSC represents a potentially significant new treatment option for the millions suffering from hair loss. Of the 87 million people in the United States that suffer from hair loss, it is estimated that only 2-7% seek surgical or pharmacological treatment. The same is true internationally due to the general lack of effective medical options for this widespread condition.

"Hair restoration treatments range in effectiveness and invasiveness. All of the current treatment options share the common goal of saving and redistributing existing hairs," said Dr. Craig Ziering. "For the millions of men and women who grapple every day with their hair loss, the results of our HSC trial indicate the potential for a phenomenal treatment option that stimulates growth of new hairs along with increasing the thickness of existing hairs. Histogen's HSC represents a potentially major paradigm shift from conventional treatment options to one that can promote the growth of new or dormant hairs using principles of the body's own regenerative mechanisms."

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developin
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Histogen Aesthetics Launches ReGenica Rejuvenation System
2. Histogen to Present Preliminary Hair Regrowth Clinical Results at Stem Cell Summit
3. David Bagley Joins Histogen as President
4. Histogen Featured on Economic Report Television Series
5. Histogen Welcomes Dr. Hyma Gollamudi as Chief Business Officer
6. Histogen Announces Start of Hair Regrowth Clinical Evaluation
7. Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine
8. Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board
9. Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market
10. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
11. Free Webinar on Safer Clinical Hand-Offs Offered by Compirion Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... International Corporation (NASDAQ: PRXL ) announced today ... Conference in New York.  Ingo Bank , Senior ... a presentation on PAREXEL and discussing business developments at ... A live webcast of the discussion will be ... www.PAREXEL.com in the Upcoming Events portion of ...
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
... Therapeutics, Inc. (PTC) today announced that Clare Kennedy has ... In this role, she will report to Theresa Natalicchio, ... PTC,s patient services and distribution functions focusing on product ... http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) , , ...
... , - Results from a randomized Phase ... Meeting -, , , MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ ... AIM:YMBA), a life sciences product development company that identifies and ... stages of development, today reported that results from a randomized ...
Cached Biology Technology:UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 4NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 5NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 6NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 7NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 8
(Date:8/20/2014)... 2014  The second annual Biometrics UnPlugged Executive ... Tampa, Florida on September 15, 2014, ... Technology and Strategy at Samsung, and Philippe de ... of this year,s event is Mobility at the ... "Biometrics UnPlugged: Mobility at the Crossroads of Commerce ...
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
(Date:8/19/2014)... a lemur. It,s not an African Bush Baby or even ... and downright "cool" primate from Southeast Asia. , "It,s really ... Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. ... furry body; a long tail with a furry tuft at ... look a bit like the disks on the digits of ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... an unlikely new target: molecules. Scientists at the National ... of molecular data similar to Facebook,s recently debuted graph ... to find all their New York-living, beer-drinking buddies in ... rapidly sift through enormous chemical and biological data sets ...
... July 18, 2013 -- Scientists at Wake Forest Baptist Medical ... effect of impacts to the head incurred by football players. ... capture players, exposure to the risk of concussion over the ... magnitude of all impacts, said senior author of the study ...
... Health Summit held at the Mayflower Renaissance hotel in Washington ... to scientists, writers and researchers looking to learn and discuss ... links mushrooms to today,s and future health issues. ... world,s top scientists, researchers and nutrition experts who will provide ...
Cached Biology News:Facebook for molecules 2Facebook for molecules 3Scientists develop new way to measure cumulative effect of head hits in football 2Scientists develop new way to measure cumulative effect of head hits in football 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: